NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free EYPT Stock Alerts $16.95 -0.70 (-3.97%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$16.51▼$17.9550-Day Range$16.95▼$29.6352-Week Range$5.67▼$30.99Volume1.39 million shsAverage Volume1.00 million shsMarket Capitalization$844.62 millionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get EyePoint Pharmaceuticals alerts: Email Address EyePoint Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.6% Upside$34.00 Price TargetShort InterestBearish13.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 7 Articles This WeekInsider TradingAcquiring Shares$10.49 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.73) to ($2.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 starsMedical Sector562nd out of 909 stocksAnalytical Instruments Industry21st out of 26 stocks 3.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.75% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 4.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 2.6 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have bought 629.68% more of their company's stock than they have sold. Specifically, they have bought $10,489,223.00 in company stock and sold $1,437,509.00 in company stock.Percentage Held by Insiders13.05% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($1.73) to ($2.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More EYPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYPT Stock News HeadlinesApril 20, 2024 | msn.comVeru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare moversApril 19, 2024 | markets.businessinsider.comBuy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMDApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 13, 2024 | markets.businessinsider.comStrong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic TherapiesApril 2, 2024 | globenewswire.comEyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsMarch 18, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 9, 2024 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%April 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. March 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Clinical Trials and Market Expansion PotentialMarch 8, 2024 | markets.businessinsider.comCritical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To KnowMarch 8, 2024 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 8, 2024 | finance.yahoo.comQ4 2023 EyePoint Pharmaceuticals Inc Earnings CallMarch 7, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023March 7, 2024 | investorplace.comEYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | seekingalpha.comEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call TranscriptMarch 7, 2024 | msn.comEyePoint Pharmaceuticals GAAP EPS of -$0.33 beats by $0.16, revenue of $14M beats by $5.3MMarch 7, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy RatingMarch 7, 2024 | washingtonpost.comEyePoint Pharmaceuticals: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsMarch 6, 2024 | msn.comEyePoint Pharmaceuticals Q4 2023 Earnings PreviewMarch 6, 2024 | benzinga.comA Preview Of EyePoint Pharmaceuticals's EarningsMarch 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for EyePoint Pharmaceuticals Amid Strategic Leadership Changes and Promising Pipeline OutlookMarch 4, 2024 | finanznachrichten.deEyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerMarch 4, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerFebruary 29, 2024 | finance.yahoo.comEyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024See More Headlines Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/22/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees121Year Founded1987Price Target and Rating Average Stock Price Target$34.00 High Stock Price Target$44.00 Low Stock Price Target$22.00 Potential Upside/Downside+96.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-153.84% Pretax Margin-153.66% Return on Equity-61.48% Return on Assets-33.49% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.39 Sales & Book Value Annual Sales$46.02 million Price / Sales18.73 Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book3.06Miscellaneous Outstanding Shares49,830,000Free Float43,328,000Market Cap$862.06 million OptionableOptionable Beta1.64 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Jay S. Duker M.D. (Age 65)President, CEO & Director Comp: $848.5kDr. John B. Landis M.S. (Age 71)Ph.D., Interim Head of R&D and Director Comp: $63.75kMr. Michael Pine (Age 47)Chief Business Officer Comp: $764.85kMr. George O. Elston (Age 59)Executive VP & CFO Comp: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Comp: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerDr. Marcia Sellos-Moura Ph.D.Senior Vice President of Program LeadershipMore ExecutivesKey CompetitorsStandard BioToolsNASDAQ:LABCytek BiosciencesNASDAQ:CTKBQuanterixNASDAQ:QTRXPacific Biosciences of CaliforniaNASDAQ:PACBNautilus BiotechnologyNASDAQ:NAUTView All CompetitorsInsiders & InstitutionsCormorant Asset Management, LpBought 581,765 shares on 4/18/2024Total: $10.49 M ($18.03/share)Woodstock CorpBought 8,525 shares on 4/9/2024Ownership: 0.062%Healthcare of Ontario Pension Plan Trust FundBought 137,000 shares on 3/21/2024Ownership: 0.275%Sierra Summit Advisors LLCBought 22,613 shares on 2/22/2024Ownership: 0.048%Quarry LPSold 9,000 shares on 2/20/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions EYPT Stock Analysis - Frequently Asked Questions Should I buy or sell EyePoint Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks. What is EyePoint Pharmaceuticals' stock price target for 2024? 6 analysts have issued 12-month target prices for EyePoint Pharmaceuticals' stock. Their EYPT share price targets range from $22.00 to $44.00. On average, they anticipate the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts. How have EYPT shares performed in 2024? EyePoint Pharmaceuticals' stock was trading at $23.11 at the beginning of the year. Since then, EYPT shares have decreased by 26.7% and is now trading at $16.95. View the best growth stocks for 2024 here. When is EyePoint Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our EYPT earnings forecast. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.27. The firm had revenue of $14.03 million for the quarter, compared to analyst estimates of $8.71 million. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative trailing twelve-month return on equity of 61.48%. During the same period in the prior year, the business posted ($0.61) EPS. What ETFs hold EyePoint Pharmaceuticals' stock? ETFs with the largest weight of EyePoint Pharmaceuticals (NASDAQ:EYPT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Invesco Biotechnology & Genome ETF (PBE).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did EyePoint Pharmaceuticals' stock split? Shares of EyePoint Pharmaceuticals reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). Who are EyePoint Pharmaceuticals' major shareholders? EyePoint Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Woodstock Corp (0.06%). Insiders that own company stock include Cormorant Asset Management, Lp, Dario A Paggiarino, David Scott Jones, Ew Healthcare Partners, LP, Michael Craig Pine and Ye Liu. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EYPT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
